Latest Breaking News On - Kohei shitara - Page 6 : comparemela.com

Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 SPOTLIGHT Trial as First-Line Treatment in Claudin 18.2 Positive, HER2-Negative Locally Advanced or Metastatic Gastric and Gastroesophageal Junction (GEJ) Cancers

Zolbetuximab is an investigational first-in-class monoclonal antibody targeting Claudin 18.2 (CLDN18.2), for the first-line treatment of patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

United statesUnited kingdomKenji yasukawaAhsan arozullahKohei shitaraNational cancer center hospitalAstellas pharma incEnd results programNational cancer instituteHead of development therapeutic areasDepartment of gastrointestinal oncologyAmerican cancer societyPrimary investigatorGastrointestinal oncologyNational cancer center hospital eastSenior vice president

Astellas meets primary endpoint in gastric cancer study

Astellas has announced positive topline results from its phase 3 SPOTLIGHT clinical trial evaluating the efficacy and safety of zolbetuximab.

Ahsan arozullahKohei shitaraNational cancer center hospitalAstellas pharma incDepartment of gastrointestinal oncologyAstellas pharmaGastrointestinal oncologyNational cancer center hospital east

Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 SPOTLIGHT Trial as First-Line Treatment in Claudin 18.2 Positive, HER2-Negative Locally Advanced or Metastatic Gastric and Gastroesoph

Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 SPOTLIGHT Trial as First-Line Treatment in Claudin 18.2 Positive, HER2-Negative Locally Advanced or Metastatic Gastric and Gastroesoph
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomKenji yasukawaAhsan arozullahKohei shitaraNational cancer center hospitalNational cancer instituteDepartment of gastrointestinal oncologyEnd results programAstellas pharma incAstellasastellas pharma incHead of development therapeutic areasPrnewswire astellas pharma incAmerican cancer societyPrimary investigatorGastrointestinal oncology

Late-Breaking Presentation on the Phase 3 LEAP-002 Study Investigating the Lenvatinib plus Pembrolizumab Combination Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

Eisai Co., Ltd.

United statesFrance generalHaruo naitoPetera kaufmanCamillog portaLos angelesKohei shitaraRichards finnVicky makkerGeffen school of medicineNational cancer center hospitalUniversity of californiaUniversity of bariMerck sharp dohme corpMerck co incInterdisciplinary department of medicine

More Data for Upfront PD-1 Inhibition in Gastric, Esophageal Cancer

Updates from two landmark trials show consistent benefits across subgroups, PD-L1 expression

Kohei shitaraCharles bankheadStefano cascinuJean philippe metgesNational cancer center hospitalSan raffaele research hospitalNational institute of cancerUniversity hospital centerMedpage todayGastrointestinal cancers symposiumNational cancer center hospital eastNational institute